These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 19525489)

  • 1. Primary leukocyte screens for innate immune agonists.
    Goodchild A; Nopper N; Craddock A; Law T; King A; Fanning G; Rivory L; Passioura T
    J Biomol Screen; 2009 Jul; 14(6):723-30. PubMed ID: 19525489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response modifiers--mode of action.
    Schiller M; Metze D; Luger TA; Grabbe S; Gunzer M
    Exp Dermatol; 2006 May; 15(5):331-41. PubMed ID: 16630072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model.
    Ma Y; Poisson L; Sanchez-Schmitz G; Pawar S; Qu C; Randolph GJ; Warren WL; Mishkin EM; Higbee RG
    Immunology; 2010 Jul; 130(3):374-87. PubMed ID: 20331478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-stimulation with TLR7/8 and TLR9 agonists induce down-regulation of innate immune responses in sheep blood mononuclear and B cells.
    Booth JS; Buza JJ; Potter A; Babiuk LA; Mutwiri GK
    Dev Comp Immunol; 2010 May; 34(5):572-8. PubMed ID: 20051250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor agonists are potent inhibitors of human immunodeficiency virus-type 1 replication in peripheral blood mononuclear cells.
    Buitendijk M; Eszterhas SK; Howell AL
    AIDS Res Hum Retroviruses; 2014 May; 30(5):457-67. PubMed ID: 24328502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLR activation pathways in HIV-1-exposed seronegative individuals.
    Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
    J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunology of TLR-independent vaccine adjuvants.
    De Gregorio E; D'Oro U; Wack A
    Curr Opin Immunol; 2009 Jun; 21(3):339-45. PubMed ID: 19493664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil.
    Patchett AL; Latham R; Brettingham-Moore KH; Tovar C; Lyons AB; Woods GM
    Dev Comp Immunol; 2015 Nov; 53(1):123-33. PubMed ID: 26182986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral danger signals control CD1d de novo synthesis and NKT cell activation.
    Raftery MJ; Winau F; Giese T; Kaufmann SH; Schaible UE; Schönrich G
    Eur J Immunol; 2008 Mar; 38(3):668-79. PubMed ID: 18253929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.
    Chen XZ; Mao XH; Zhu KJ; Jin N; Ye J; Cen JP; Zhou Q; Cheng H
    Arch Dermatol Res; 2010 Jan; 302(1):57-65. PubMed ID: 19578865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
    Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
    J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.
    Zhang X; Kraft A; Broering R; Schlaak JF; Dittmer U; Lu M
    Expert Opin Drug Discov; 2012 Jul; 7(7):597-611. PubMed ID: 22607384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant activity on human cells in vitro.
    De Wit D; Goldman M
    Methods Mol Biol; 2010; 626():103-16. PubMed ID: 20099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of human natural killer cells by the novel innate immune modulator recombinant Eimeria antigen.
    Aylsworth CF; Aldhamen YA; Seregin SS; Godbehere S; Amalfitano A
    Hum Immunol; 2013 Aug; 74(8):916-26. PubMed ID: 23639554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection.
    Gill N; Davies EJ; Ashkar AA
    Am J Reprod Immunol; 2008 Jan; 59(1):35-43. PubMed ID: 18154594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells.
    Krumbiegel D; Zepp F; Meyer CU
    Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the analyst's couch: TLR-targeted therapeutics.
    Hoffman ES; Smith RE; Renaud RC
    Nat Rev Drug Discov; 2005 Nov; 4(11):879-80. PubMed ID: 16299917
    [No Abstract]   [Full Text] [Related]  

  • 18. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I.
    Miyazaki M; Kanto T; Inoue M; Itose I; Miyatake H; Sakakibara M; Yakushijin T; Kakita N; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    J Med Virol; 2008 Jun; 80(6):980-8. PubMed ID: 18428149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New perspective in immunotherapy: local imiquimod treatment].
    Kemény L; Nagy N
    Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.